# Opioid Use Disorder: A Team-based Approach

**Friday, September 13, 2019 • DoubleTree Hotel (6505 North IH-35)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Course Topic/ Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30am – 12:30pm</td>
<td><strong>Participant Check-in &amp; LUNCH</strong></td>
</tr>
</tbody>
</table>
| 12:30pm – 1:00pm  | **Introduction: The Opioid Crisis**  
Lucas G. Hill, PharmD, BCPS, BCACP (*Program Planning Chair*)  
Clinical Assistant Professor, UT College of Pharmacy  
Director & Principal Investigator, Operation Naloxone  
- Examine the epidemiology of opioid use disorder (OUD), overdose, and related complications.  
- Discuss how OUD may be encountered or addressed by a range of healthcare professionals. |
| 1:00pm – 1:45pm  | **Supportive Behavioral Interventions**  
Caroline Hedenberg, LCSW  
Collaborative Care Clinician, CARMAhealth  
- Describe key principles of the evidence-based practice known as SBIRT.  
- Identify supportive resources for clinical application of SBIRT  
- Describe key principles of Motivational Interviewing (MI).  
- Identify supportive resources for clinical application of MI. |
| 1:45pm – 2:00pm  | **Supportive Behavioral Interventions – Case-based Exercise and/or Interactive Q/A Discussion**  
Caroline Hedenberg, LCSW  
- Examine the application of SBIRT and MI in the identification/treatment of OUD. |
| 2:00pm – 2:15pm  | **BREAK** |
| 2:15pm – 3:00pm  | **Medication-Assisted Recovery 101**  
David Walsh, MSN, RN, PMHNP-BC  
Chief Operations Officer, CARMAhealth  
- Compare three FDA-approved medications for OUD treatment according to basic pharmacology and implications for treatment.  
- Examine evidence regarding patient outcomes using these agents for OUD.  
- Contrast barriers to accessing FDA-approved medications for OUD treatment. |
| 3:00pm – 3:15pm  | **Medication-Assisted Recovery 101 – Case-based Exercise and/or Interactive Q/A Discussion**  
David Walsh, MSN, RN, PMHNP-BC  
- Practice applying medication therapy for the treatment of OUD using case exercises.  
- Examine the variable impact of the FDA-approved agents on access to recovery supports. |
| 3:15pm – 3:30pm  | **BREAK** |
| 3:30pm – 4:15pm  | **Medication-Assisted Recovery 201**  
Carlos F. Tirado, MD, MPH  
Chief Medical Officer, CARMAhealth  
Clinical Associate Professor, Dell Medical School  
- Recall common comorbidities encountered in patients with severe OUD.  
- Describe team-based models for comprehensive treatment of OUD and comorbidities.  
- Discuss current controversies and ethical issues related to OUD treatment. |
| 4:15pm – 4:30pm  | **Medication-Assisted Recovery 201 – Case-based Exercise and/or Interactive Q/A Discussion**  
Carlos F. Tirado, MD, MPH  
- Practice developing a comprehensive treatment plan for OUD utilizing a team-based approach.  
- Identify the role(s) pharmacists may have in comprehensive treatment plans. |

**Course Concludes / Dinner Served (Complimentary)**